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Abstract
Background. The aim was to establish the features of hemodynamic and metabolic parameters in obese patients 
with true and pseudo-resistant arterial hypertension (AH).
Material and methods. The study included 200 patients with uncontrolled AH and obesity. Patients were initially 
prescribed dual antihypertensive therapy. Those patients who did not reach target blood pressure (BP) levels after 
3 months on dual therapy were additionally prescribed a third antihypertensive drug. Of the 98 patients who were 
assigned to triple therapy, 48 patients did not reach target BP (27 patients had pseudo-resistant and 21 patients had 
true resistant AH). These patients were additionally prescribed a fourth antihypertensive drug (spironolactone). The 
effectiveness of the treatment was evaluated 6 months after the start of antihypertensive therapy.
Results. After 6 months of therapy, unlike patients without resistance, individuals with resistant AH had more pro-
nounced cardiovascular remodeling and metabolic disorders, disbalance of oxidative stress-antioxidant protection, 
proinflammatory activity and higher activity of the renin-angiotensin-aldosterone system. Patients with true resist-
ance differed from pseudo-resistant patients by having significantly lower body mass index (BMI); in the absence of 
differences in BP levels, cardiovascular remodeling, lipid and carbohydrate profiles, patients with true resistance had 
significantly higher levels of aldosterone, higher activity of oxidative stress system, lower levels of general antioxidant 
protection, higher adiponectin levels, and lower leptin level.
Conclusions. Obese patients with true resistance differed from pseudo-resistant patients by having significantly 
lower BMI, higher aldosterone levels, more pronounced imbalance of the system of oxidative stress-antioxidant 
protection and less pronounced adipokine imbalance.
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Introduction
Resistant hypertension (RH) is an important cause 
of cardiovascular morbidity and mortality. According 
to the definition of resistance presented in the 2018 
ESC/ESH Guidelines for the management of arterial 
hypertension (AH), RH should be diagnosed when the 
recommended treatment strategy fails to lower office 
systolic and diastolic blood pressure (SBP and DBP) 
values to less than 140 mm Hg and/or less than 90 
mm Hg, respectively, and the inadequate control of BP 
is confirmed by ambulatory or home BP monitoring 
in patients whose adherence to therapy has been con-
firmed [1]. As indicated in the specified Guidelines, the 
treatment strategy should include appropriate lifestyle 
measures and treatment with optimal or best tolerated 
doses of three or more drugs, which should include 
a diuretic, typically an angiotensin-converting enzyme 
(ACE) inhibitor (or an angiotensin II receptor block-
ers) and a calcium channel blockers (CCB) [1].
At the same time, pseudo-resistant hypertension 
(due to low compliance with treatment, the white-
coat phenomenon, increased calcification of the 
shoulder arteries and a number of other causes) and 
true resistance should be distinguished. Both true 
and pseudo-resistant hypertensions represent a big 
problem not only in BP control, but also in those 
possible adverse cardiovascular events, the develop-
ment of which is associated with failure to achieve 
target BP levels.
Resistant hypertension patients require a multi-
modal approach to control BP. In most patients, 
RH can be influenced by optimizing combination 
antihypertensive therapy to improve compliance and 
lifestyle correction [1, 2]. As indicated in the 2018 
ESC/ESH Guidelines [1], in the case of RH, an 
antagonist of mineralocorticoid receptors should be 
additionally prescribed to patients, due to its effect 
on a number of pathogenetic mechanisms such as 
the suppression of macrophage infiltration and im-
provement of endothelium-dependent vasodilatation 
(EDVD) [3–6]. There is evidence of a more pro-
nounced hypotensive effect of aldosterone blockers 
in patients with increased waist circumference than 
in patients with its normal values [7–9].
Given the high prevalence of comorbidity of AH 
and obesity on the one hand and a large percent-
age of people with insufficiently controlled AH on 
the other hand, the study of the features of true 
resistance and pseudo-resistance in obese patients 
deserves attention.
The aim of the study was to establish the features 
of hemodynamic and metabolic parameters in obese 
patients with true and pseudo-resistant AH.
Material and methods
The study included 200 patients with uncontrolled 
AH and obesity classes I–II (the age 45–55 years). 
Antihypertensive therapy was prescribed in accor-
dance with the 2018 ESC/ESH Guidelines for the 
management of AH [1]. Dual antihypertensive ther-
apy (ACE inhibitor and CCB) was administered 
to patients first. Those patients who did not reach 
the target BP levels of dual therapy after 3 months 
were further prescribed a third antihypertensive drug 
(the thiazide-like diuretic indapamide). Of the 98 
patients who were assigned to triple therapy, 48 pa-
tients did not reach the target BP levels: 27 patients 
had pseudo-resistant hypertension (due to low com-
pliance with treatment and insufficient adherence to 
the physician’s instructions to ensure adequate levels 
of physical activity), and 21 patients had true RH 
(did not achieve target BP levels with triple antihy-
pertensive therapy and sufficient physical activity). 
These patients were additionally prescribed a fourth 
antihypertensive drug — spironolactone. The effec-
tiveness of the treatment was evaluated 6 months 
after the start of antihypertensive therapy.
Adherence to treatment was evaluated on the basis 
of the patient’s diary, which included the time of tak-
ing a fixed combination of antihypertensive drugs 
and BP levels in the morning and evening hours. In 
addition, in the diary, the patient entered the infor-
mation on the number of steps taken during the day, 
which were measured using a pedometer. 
Physical examination of patients included mea-
surements of height, body weight, and BMI calcula-
tion. Patients’ waist circumference (WC) and hip 
circumference (HC) were measured, and waist-to-
hip ratio was calculated. Office BP was measured in 
accordance with the 2018 ESC/ESH Guidelines for 
the management of AH [1]. Pulse BP was evaluated 
as the difference between SBP and DBP. Average BP 
was calculated by the formula: 
Average BP = 0.42 × (SBP – DBP) + DBP
Lipid metabolism was assessed by total choles-
terol, triglycerides, LDL and HDL cholesterol. Car-
bohydrate metabolism was assessed by blood glucose, 
HbA1c and insulin levels. Insulin resistance (IR) was 
determined by the HOMA model. The activity of the 
renin–angiotensin–aldosterone system (RAAS) was 
evaluated by the levels of aldosterone and renin plas-
ma, as well as by the aldosterone-renin ratio (ARR). 
The inflammatory activity was evaluated by the levels 
of interleukin 6 (IL-6) and C-reactive protein (CRP). 
The functional state of adipose tissue was assessed by 
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blood levels of leptin and adiponectin. The state of 
the prooxidant system was evaluated by the levels of 
molecular products of lipid peroxidation — diene 
conjugates (DC) and malonic dialdehyde (MDA), 
and the state of the antioxidant protection system 
— by the total antioxidant activity.
Morphofunctional properties of the myocardium 
were evaluated during ultrasound examination of 
the heart in one-dimensional, two-dimensional and 
Doppler modes by conventional methods. The vol-
umes of left and right atria (LA and RA, respective-
ly), end-systolic and end-diastolic diameters (ESD 
and EDD, respectively) of the left ventricle (LV), 
diameters of LA and aorta (LAD and AD, respec-
tively) were evaluated. The ejection fraction (EF) was 
calculated by the formula: 
EF = (EDV – ESV) / EDV
where ESV and EDV are the end-systolic and end-
diastolic LV volumes, respectively.
The thickness of the posterior wall of the LV and 
the thickness of the interventricular septum in the 
systole (TPWs and TIVSs, respectively) and diasto-
le (TPWd and TIVSd, respectively) were measured. 
The relative wall thickness of the LV (RWT) was 
calculated by the formula: 
RWT = (TPWd + TIVSd) / EDD
The LV myocardial mass index (MMILV) was 
calculated as the ratio of the LV myocardial mass 
(MMLV) to the surface area of the body (S): 
MMILV = MMLV / S
Left ventricular diastolic function was evaluated 
by pulmonary artery blood flow and transmitral dia-
stolic blood flow in pulsed Doppler with the deter-
mination of the following parameters: maximum 
early LV filling rate in spectral mode (E), maximum 
late (atrial) filling speed (A), ratio of maximal rates 
of early and late filling of LV at spectral mode (E/A), 
time of isovolumic relaxation of LV (IVRT), time 
of deceleration early diastolic flow rate (DT), maxi-
mum early LV filling rate at tissue mode (e), mean 
pulmonary artery pressure (AP) by Kitabatake, ratio 
of E and e (E/e).
The degree of EDVD was determined in the sam-
ple with reactive hyperemia. At the same time, the 
intima-media thickness (IMT) in the carotid artery 
(CA) was measured 2 cm more proximal to the bifur-
cation of the common CA. The pulse wave velocity 
(PWV) in the CA was determined by the W-Track 
method; determination of the PWV in the abdomi-
nal aorta (AA) was performed using a phased sensor.
The statistical processing of the obtained data was 
carried out using the package of statistical software 
“SPSS 17” (IBM), Microsoft Office Exel-2003. The 
data are presented as mean values ± standard devia-
tion. Significance was set at a p value of < 0.05 in 
all cases.
Results
The comparative assessment of patients’ values in 
the presence and absence of RH after 6 months of 
therapy was first of all performed (Tab. 1). It was 
found that after 6 months of therapy, patients with 
RH had higher BMI and higher BP levels compared 
to patients without this condition. 
It should be noted that patients with RH also had 
more pronounced cardiovascular remodeling (higher 
IMT CA, IVS, TPW, TIVS LVM, E/e and lower 
EF), higher levels of triglycerides, insulin, HbA1c, 
more pronounced IR (which was confirmed by great-
er HOMA-IR), greater imbalance of adipokines, 
proinflammatory activity and higher RAAS activity 
(Tab. 1).
A comparative assessment of pseudo-resistance 
and true resistance showed that patients with true 
resistance differed from pseudo-resistant patients by 
having significantly lower BMI (p = 0.02) (Tab. 2). 
In addition, in the absence of differences in BP levels, 
cardiovascular remodeling, and lipid and carbohy-
drate profiles, patients with true resistance had signifi-
cantly higher levels of aldosterone (p = 0.04), higher 
activity of oxidative stress (MDA, p = 0.01 and DC, 
p = 0.03), a lower level of total antioxidant protection 
(p = 0.00), a higher level of adiponectin (p = 0.00), 
and a lower level of leptin (p = 0.00), compared with 
pseudo-resistant patients.
Discussion
The literature suggests that between 50% and 80% of 
patients with AH who are prescribed antihyperten-
sive drugs show suboptimal adherence to treatment. 
In many cases, this high percentage of failure to reach 
target BP levels is at least in part due to the large 
number of drugs, the complexity of their dosage, the 
high incidence of adverse reactions, poor patient-
physician relationships, and the inertia of the clini-
cian with reduced adherence to treatment [2, 10].
Renin–angiotensin–aldosterone system plays a key 
role in the BP regulation, and its excessive activity 
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Table 1. Comparative assessment of indicators in patients 6 months after treatment, depending on the presence of resistant arterial 
hypertension (AH)
Indicators Resistant AH is absent(n = 152)
Resistant AH is present
(n = 48) p
Weight [kg] 92.62 ± 9.65 98.56 ± 7.51 0.00
BMI [kg/m2] 31.85 ± 2.53 34.44 ± 1.37 0.00
Waist [cm] 99.13 ± 6.79 101.65 ± 6.35 0.02
Hip [cm] 108.38 ± 10.39 105.52 ± 5.54 0.07
Waist-to-hip ratio 0.96 ± 0.60 0.97 ± 0.08 0.97
SBP [mm Hg] 136.34 ± 1.83 138.05 ± 1.43 0.00
DBP [mm Hg] 86.43 ± 1.01 88.23 ± 0.75 0.00
Pulse BP [mm Hg] 48.90 ± 2.03 49.13 ± 1.62 0.49
Average BP [mm Hg] 103.87 ± 0.88 105.86 ± 0.92 0.00
Heart rate [bpm] 68.89 ± 3.22 68.83 ± 3.70 0.92
IMT CA [mm] 0.87 ± 0.08 0.93 ± 0.08 0.00
IMT CA bifurcation [mm] 1.26 ± 0.15 1.29 ± 0.13 0.19
PWV CA [m/s] 7.84 ± 1.04 7.82 ± 0.99 0.90
PWV AA [m/s] 7.75 ± 1.03 7.80 ± 1.00 0.75
EDVD (%) 7.89 ± 1.29 7.92 ± 0.91 0.86
Total cholesterol [mmol/L] 5.72 ± 0.47 5.79 ± 0.38 0.31
Triglycerides [mmol/L] 1.70 ± 0.28 1.95 ± 0.42 0.00
LDL cholesterol [mmol/L] 4.56 ± 0.47 4.72 ± 0.45 0.08
HDL cholesterol, [mmol/L] 1.04 ± 0.13 1.03 ± 0.19 0.37
Glucose [mmol/L] 4.66 ± 0.30 4.69 ± 0.29 0.49
Insulin [mU/mL] 11.19 ± 4.02 16.36 ± 2.80 0.00
HOMA-IR 2.32 ± 0.85 3.39 ± 0.60 0.00
HbA1c (%) 4.68 ± 0.30 4.82 ± 0.32 0.02
Total antioxidant activity [mmol/L] 1.26 ± 0.06 1.18 ± 0.06 0.00
MDA [nmol/mL] 30.38 ± 2.53 32.80 ± 1.72 0.00
DC [nmol/mL] 27.09 ± 3.57 31.08 ± 3.45 0.00
IL-6 [ng/mL] 106.75 ± 6.94 109.82 ± 7.53 0.01
CRP [ng/mL] 4.26 ± 0.75 4.51 ± 0.72 0.04
Aldosteron [ng/dl] 14.27 ± 1.62 14.76 ± 1.32 0.32
Renin, ng/ml/hour 2.19 ± 0.46 2.53 ± 0.47 0.01
ARR 7.60 ± 1.56 6.11 ± 1.54 0.00
Adiponectin [ng/mL] 7.49 ± 1.06 8.09 ± 0.98 0.00
Leptin [ng/mL] 11.61 ± 2.20 12.73 ± 2.03 0.00
IVSd [sm] 1.10 ± 0.12 1.15 ± 0.11 0.01
IVSs [sm] 1.30 ± 0.14 1.36 ± 0.13 0.01
TPWd [sm] 1.09 ± 0.13 1.14 ± 0.14 0.02
TPWs [sm] 1.51 ± 0.33 1.55 ± 0.36 0.53
TIVSd [sm] 4.98 ± 0.32 5.04 ± 0.41 0.30
TIVSs [sm] 3.12 ± 0.25 3.20 ± 0.30 0.04
EF (%) 67.13 ± 3.20 65.86 ± 2.24 0.01
LVM [g] 244.72 ± 60.55 267.79 ± 73.88 0.03
LVMMI [g/m2] 120.00 ± 29.06 128.69 ± 35.85 0.09
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Table 2. Comparison of patients with pseudo-resistant and true resistant arterial hypertension (AH)
Indicators Pseudo-resistant AH(n = 27)
True resistant AH
(n = 21) p
Weight [kg] 99.56 ± 8.37 97.29 ± 6.21 0.43
BMI [kg/m2] 34.83 ± 1.28 33.93 ± 1.35 0.02
Waist [cm] 101.56 ± 6.73 101.76 ± 6.00 0.91
Hip [cm] 105.26 ± 5.40 105.86 ± 5.82 0.79
Waist-to-hip ratio 0.97 ± 0.08 0.96 ± 0.08 0.95
SBP [mm Hg] 137.30 ± 1.52 137.43 ± 1.48 0.71
DBP [mm Hg] 88.25 ± 0.82 88.41 ± 0.84 0.93
Pulse BP [mm Hg] 49.07 ± 1.62 49.19 ± 1.66 0.76
Average BP [mm Hg] 104.03 ± 0.96 104.92 ± 0.79 0.88
Heart rate [bpm] 68.78 ± 4.47 68.90 ± 2.51 0.47
IMT CA [mm] 0.94 ± 0.08 0.92 ± 0.08 0.41
IMT CA bifurcation [mm] 1.31 ± 0.12 1.29 ± 0.14 0.06
PWV CA [m/s] 8.06 ± 1.08 7.51 ± 0.79 0.06
PWV AA [m/s] 8.00 ± 0.92 7.55 ± 1.06 0.24
EDVD (%) 7.84 ± 1.01 8.02 ± 0.77 0.25
Total cholesterol [mmol/L] 5.83 ± 0.40 5.75 ± 0.36 0.35
Triglycerides [mmol/L] 1.77 ± 0.33 1.61 ± 0.14 0.07
LDL cholesterol [mmol/L] 4.69 ± 0.49 4.77 ± 0.40 0.72
HDL cholesterol [mmol/L] 1.03 ± 0.10 1.04 ± 0.09 0.09
Glucose [mmol/L] 4.70 ± 0.32 4.61 ± 0.26 0.18
Insulin [mU/mL] 16.01 ± 2.61 16.80 ± 3.03 0.28
Table 1. Comparative assessment of indicators in patients 6 months after treatment, depending on the presence of resistant arterial 
hypertension (AH)
Indicators Resistant AH is absent(n = 152)
Resistant AH is present
(n = 48) p
RWT 0.44 ± 0.04 0.46 ± 0.04 0.01
LAD [mm] 37.33 ± 3.03 37.29 ± 3.54 0.95
AD [mm] 32.47 ± 1.60 32.07 ± 0.59 0.09
Mean pulmonary AP [mm Hg] 15.54 ± 3.12 15.71± 2.97 0.75
RAV [mL] 38.31 ± 4.90 37.40 ± 3.81 0.24
LAV [mL] 46.71 ± 4.64 48.31 ± 4.09 0.03
E [cm/s] 69.91 ± 11.68 67.49 ± 6.18 0.17
A [cm/s] 78.99 ± 11.11 77.67 ± 8.05 0.46
E/A 0.94 ± 0.19 0.90 ± 0.09 0.19
DT [s] 0.15 ± 0.09 0.15 ± 0.09 0.96
IVRT [s] 0.10 ± 0.02 0.11 ± 0.02 0.11
E [cm/s] 12.61 ± 2.54 11.57 ± 2.28 0.01
E/e 5.67 ± 1.04 6.04 ± 1.25 0.04
A — maximum late (atrial) filling speed; AA — aortic arch; AP — artery pressure; ARR — aldosterone-renin ratio; BMI — body mass index; BP — blood pressure; CA — carotid artery; CRP — C-reactive protein;  
DBP — diastolic blood pressure; DC — diene conjugates; DT — time of deceleration early diastolic flow rate; E — filling rate in spectral mode; e — maximum early LV filling rate at tissue mode; E/A — ratio of maximal 
rates of early and late filling of LV at spectral mode; E/e — ratio of E and e; EDVD —  endothelium-dependent vasodilatation; EF — ejection fraction; HbA1c — glycated hemoglobin; HDL — high density lipoprotein; 
IL-6 — interleukin 6; HOMA-IR — Homeostatic Model Assessment for Insulin Resistance; IMT — intima-media thickness; IVRT — time of isovolumic relaxation of LV; IVSd, interventricular septum (diastole);  
IVSs, interventricular septum (systole); LDL — low-density lipoprotein; LVM — left ventricular mass; MDA — malonic dialdehyde; RAV — right atrial volume; LAV — left atrial volume; SBP — systolic blood pressure; 
PWV — pulse wave velocity; TIVSd – thickness of the interventricular septum (diastole); TIVSs – thickness of the interventricular septum (systole); TPWd — thickness of the posterior wall of the left ventricle  
in diastole; TIVSd — the thickness of the interventricular septum in diastole
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eration of fibrosis processes in the heart and vessels 
[11–14].
It is known that most obese individuals have 
a high level of blood aldosterone, and as the obe-
sity progresses, the concentration of this hormone 
is responsible for a wide range of side effects in the 
cardiovascular system, which, due to the increased 
concentration of angiotensin II and aldosterone, lead 
to an increase in BP, an increase in extracellular fluid 
volume, activation of hypercoagulation, and accel-
Table 2. Comparison of patients with pseudo-resistant and true resistant arterial hypertension (AH)
Indicators Pseudo-resistant AH(n = 27)
True resistant AH
(n = 21) p
HOMA-IR 3.34 ± 0.57 3.44 ± 0.64 0.44
HbA1c (%) 4.65 ± 0.33 4.71 ± 0.27 0.17
Total antioxidant activity [mmol/L] 1.22 ± 0.05 1.16 ± 0.05 0.00
MDA [nmol/mL] 32.24 ± 1.53 33.24 ± 1.76 0.01
DC [nmol/mL] 32.54 ± 2.78 29.95 ± 3.54 0.03
IL-6 [ng/mL] 109.55 ± 7.44 111.91 ± 8.31 0.06
CRP [ng/mL] 4.32 ± 0.61 4.66 ± 0.77 0.17
Aldosteron [ng/dL] 14.34 ± 1.23 15.09 ± 1.31 0.04
Renin [ng/mL/hour] 2.57 ± 0.44 2.50 ± 0.50 0.86
ARR 5.80 ± 1.38 6.35 ± 1.64 0.23
Adiponectin [ng/mL] 7.44 ± 0.64 8.93 ± 0.67 0.00
Leptin [ng/mL] 13.72 ± 1.93 11.46 ± 1.34 0.00
IVSd [sm] 1.15 ± 0.09 1.16 ± 0.13 0.64
IVSs [sm] 1.37 ± 0.13 1.34 ± 0.14 0.36
TPWd [sm] 1.14 ± 0.12 1.15 ± 0.17 0.15
TPWs [sm] 1.51 ± 0.28 1.60 ± 0.44 0.70
TIVSd [sm] 5.01 ± 0.35 5.07 ± 0.48 0.78
TIVSs [sm] 3.19 ± 0.27 3.22 ± 0.34 0.63
EF (%) 65.82 ± 1.82 65.90 ± 2.74 0.33
LVM [g] 262.76 ± 57.30 274.26 ± 92.09 0.45
LVMMI [g/m2] 126.05 ± 29.86 132.08 ± 42.89 0.72
RWT 0.46 ± 0.04 0.46 ± 0.04 0.91
LAD [mm] 37.38 ± 3.65 37.19 ± 3.47 0.21
AD [mm] 31.98 ± 0.68 32.18 ± 0.44 0.01
Mean pulmonary AP [mm Hg] 15.75 ± 3.06 15.64 ± 2.93 0.29
RAV [mL] 37.14 ± 3.71 37.73 ± 4.00 0.61
LAV [mL] 48.42 ± 4.46 48.18 ± 3.67 0.80
E [cm/s] 66.09 ± 6.70 69.28 ± 5.04 0.07
A [cm/s] 75.83 ± 7.33 73.94 ± 8.25 0.26
E/A 0.89 ± 0.12 0.91 ± 0.10 0.05
DT [s] 0.16 ± 0.12 0.13 ± 0.03 0.11
IVRT [s] 0.11 ± 0.02 0.12 ± 0.03 0.07
E [cm/s] 11.33 ± 2.03 11.87 ± 2.58 0.47
E/e 6.00 ± 1.15 6.10 ± 1.39 0.86
A — maximum late (atrial) filling speed; AA — aortic arch; AP — artery pressure; ARR — aldosterone-renin ratio; BMI — body mass index; BP — blood pressure; CA — carotid artery; CRP — C-reactive protein;  
DBP — diastolic blood pressure; DC — diene conjugates; DT — time of deceleration early diastolic flow rate; E — filling rate in spectral mode; e — maximum early LV filling rate at tissue mode; E/A — ratio of maximal 
rates of early and late filling of LV at spectral mode; E/e — ratio of E and e; EDVD —  endothelium-dependent vasodilatation; EF — ejection fraction; HbA1c — glycated hemoglobin; HDL — high density lipoprotein; 
IL-6 — interleukin 6; HOMA-IR — Homeostatic Model Assessment for Insulin Resistance; IMT — intima-media thickness; IVRT — time of isovolumic relaxation of LV; IVSd, interventricular septum (diastole);  
IVSs, interventricular septum (systole); LDL — low-density lipoprotein; LVM — left ventricular mass; MDA — malonic dialdehyde; RAV — right atrial volume; LAV — left atrial volume; SBP — systolic blood pressure; 
PWV — pulse wave velocity; TIVSd – thickness of the interventricular septum (diastole); TIVSs – thickness of the interventricular septum (systole); TPWd — thickness of the posterior wall of the left ventricle  
in diastole; TIVSd — the thickness of the interventricular septum in diastole
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increases. A number of studies have found a clear 
correlation between aldosterone levels and BMI. The 
results of a large Framingham Offspring Study show 
a direct relationship between elevated plasma aldoste-
rone levels and high BP in 1688 patients [15]. It is 
possible that secondary hyperaldosteronism accom-
panying obesity also contributes greatly to the devel-
opment of AH in these patients. This relationship is 
well observed in studies on the reduction of excess 
body weight, where weight loss entails a decrease in 
the concentration of aldosterone in the blood and is 
accompanied by a decrease in BP [5, 9, 13].
Aldosterone has also been shown to adversely af-
fect carbohydrate metabolism through three major 
mechanisms: IR, reduced insulin production, and 
activation of gluconeogenesis [3, 6, 9, 12].
The data obtained in our work show that patients 
with resistant hypertension differed from non-resis-
tant patients with more pronounced cardiovascular 
remodeling, IR and metabolic disorders; it can be 
explained by the negative effect of aldosterone, which 
levels are significantly higher in RH.
Significantly lower BMI in patients with true re-
sistance could be explained by their sufficient physi-
cal activity, whereas pseudo-resistant patients in our 
study did not follow the physician’s recommenda-
tions for providing adequate levels of physical activ-
ity. That is why, in the absence of a difference in BMI 
values between true resistant and pseudo-resistant 
patients at the beginning of the study, patients with 
true RH after complex 6-month therapy (including 
increased physical activity) had significantly lower 
BMI than pseudo-resistant ones. Higher adiponectin 
levels and lower leptin levels with true resistance can 
be explained by a large decrease in body weight of 
these patients compared to pseudo-resistant ones. 
It is known that in lower body weight, adiponectin 
is higher and leptin is lower than in higher body 
weight. The more pronounced imbalance of the sys-
tem of oxidative stress-antioxidant protection in pa-
tients with true RH can be explained by significantly 
higher levels of aldosterone, compared to pseudo-
resistant patients.
Limitations of the study
Our study included only patients of a certain age 
group (45–55 years old). Perhaps in other age groups 
(or a wider age range) hemodynamic and metabolic 
parameters with true and pseudo-resistant AH would 
have different features. A limitation of our work is 
also that adherence to the therapy of our patients 
was evaluated according to their diaries, which may 
be somewhat subjective. In addition, when evaluat-
ing the effectiveness of antihypertensive therapy, we 
took into account the data of office and home BP 
monitoring, but did not perform ambulatory BP 
monitoring, which is a more sensitive method for 
identifying masked uncontrolled hypertension.
Conclusions
Thus, in our work it was found that patients with re-
sistant hypertension differed from hypertensive obese 
patients without resistance by having higher BMI 
and BP, higher levels of triglycerides, insulin, HbA1c, 
more pronounced IR, cardiovascular remodeling, 
imbalance of oxidative stress-antioxidant protection 
system, higher proinflammatory and RAAS activity. 
Patients with true resistance differed from pseudo-
resistant patients by having significantly lower BMI, 
higher aldosterone levels more pronounced imbal-
ance of the system of oxidative stress-antioxidant 
protection and less pronounced adipokines imbal-
ance.
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